GoodRx price target raised to $10 from $7 at Evercore ISI

Evercore ISI analyst Mark Mahaney raised the firm’s price target on GoodRx to $10 from $7 and keeps an In Line rating on the shares following what the firm calls “a Beat & Mixed Q2 print.” While “lackluster” topline guidance for Q3 and FY23 underscores the near-term topline variability in a business that is in the midst of a turnaround, the firm is encouraged by early signs of revenue and MAC stability and the company’s commitment to protect EBITDA margin, the analyst tells investors.